PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats Potential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settings Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a pharmatech company focused on enabling personalized medicine through robotic 3D printing, today announced that it is strategically evolving its platform focus from PatchPrint™ 3D printer to MEDBOTX™, the Company's robotic 3D printing platform designed for personalized medicines, peptides and advanced pharmaceutical dose formats.